research Chemotherapy and the Skin: Understanding Dermatologic Side Effects
Recognizing and managing skin side effects from chemotherapy improves patient quality of life and treatment success.
Search
for
Sort by
Research
180-210 / 1000+ results 
research 4-Aminopyridine Induces Nerve Growth Factor to Improve Skin Wound Healing and Tissue Regeneration
4-Aminopyridine improves skin wound healing and tissue regeneration by increasing cell growth and promoting nerve repair.
research Topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA): Efficacy findings from a phase I safety study.
Topical calcitriol may reduce hair loss from chemotherapy at higher doses.
research One of the best treatments for alopecia areata remains unpublished
DNCB is highly effective for treating alopecia areata with minimal long-term side effects.
research A comparative study on therapeutic efficacy between topical dinitrochlorobenzene and topical betamethasone in alopecia areata
DNCB is more effective than betamethasone for hair regrowth but has more side effects.
research Chrysin Increases the Therapeutic Efficacy of Docetaxel and Mitigates Docetaxel-Induced Edema
Chrysin makes docetaxel more effective and reduces its side effects in lung cancer treatment.
research Groundnut seed production manual.
Arsenic trioxide effectively treats APL, improving survival rates despite its toxicity.
research Novel electroporation-based treatments for breast cancer
Electric pulse treatments for breast cancer show promise in being safer and more effective, with fewer side effects.
research Nanoparticles in Cancer Treatment: A Narrative Review
Nanoparticles improve cancer treatment by reducing side effects and targeting cancer cells better.
research Streptomyces-derived nano-doxorubicin: Clinical status and patents granted
Nanoparticle delivery can reduce side effects of the cancer drug doxorubicin.
research IMPROVED SKIN PENETRATION AND DEPOSITION OF NAFTIFINE FROM TRANSETHOSOMES AND TRANSETHOSOMAL GEL FORMULATIONS
Transethosomal gels improve naftifine skin delivery better than Exoderil cream.
research Targeted Therapy– and Chemotherapy-Associated Skin Toxicities: Systematic Review and Meta-Analysis
Minocycline reduces acne rash, pyridoxine lowers hand-foot syndrome risk, and scalp cooling lessens hair loss from cancer treatments.
research 12-O-Tetradecanoylphorbol-13-acetate Induces Apoptosis in Renal Epithelial Cells through a Growth Signal Conflict Which Is Prevented by Activated ras1
Activated ras can protect kidney cells from a certain substance that causes cell death.
research Drug induced hair loss.
Naproxen is not the cause of hair loss in a child; it's due to a toxic event with expected hair regrowth.
research Alkylating Agents
Alkylating agents can kill cancer cells but may cause skin and allergic reactions.
research Skin toxicity of anti‐cancer therapy
Anti-cancer treatments can cause reversible hair loss, skin sensitivity, pigmentation changes, nail damage, and skin reactions, with a need for more research on managing these side effects.
research Synergistic effect of sorafenib with Platycladus orientalis (L) leaf extract on cervical cancer
Sorafenib and Platycladus orientalis leaf extract together effectively suppress cervical cancer cell growth.
research Black phosphorus nanosheets encapsulated microneedle for multifunctional therapy for androgenic alopecia
A new treatment using microneedles with black phosphorus and laser helps regrow hair effectively and safely.
research Impact of a topical lotion, CG428, on permanent chemotherapy-induced alopecia in breast cancer survivors: a pilot randomized double-blind controlled clinical trial (VOLUME RCT)
The lotion CG428 did not show effectiveness in treating permanent hair loss in breast cancer survivors.
research A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA): Final study results
Topical calcitriol (BPM31543) is safe for preventing hair loss from chemotherapy and shows some effectiveness.
research Use of chemotherapy during human pregnancy
Chemotherapy in the first trimester of pregnancy is risky, but in the second and third trimesters, it's generally safe with careful drug selection and timing.
research A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor
New treatment with green tea polyphenols and nicotinamide improves skin problems from cancer therapy.
research Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.
Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
research Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer
Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.
research 4-aminopyridine promotes accelerated skin wound healing via neurogenic-mediator expression
4-aminopyridine, a FDA-approved drug, speeds up skin wound healing and tissue regeneration.
research Efficacy and safety evaluations of topical proretinal nanoparticles
Proretinal nanoparticles are a safe and effective way to deliver retinal to the skin.
research Profile analysis of adverse events after boron neutron capture therapy for head and neck cancer: a sub-analysis of the JHN002 study
Boron neutron capture therapy for head and neck cancer can cause side effects like mouth sores and skin irritation, which vary depending on where the treatment is aimed.
research Comparison of Polynucleotide and Polydeoxyribonucleotide in Dermatology: Molecular Mechanisms and Clinical Perspectives
PN hydrates skin; PDRN heals and regenerates skin and hair.
research Norgalanthamine Stimulates Proliferation of Dermal Papilla Cells via Anagen-Activating Signaling Pathways
Norgalanthamine helps hair cells grow by activating certain pathways related to hair growth.
research Transarterial chemoembolization (TACE) combined with donafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A real-world clinical study.
The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.